21GRAMS Wins Its First Gold Lion for Branded Pharma Campaign at Cannes Lions International Festival of Creativity
'Winning at Cannes is not just about the work; it's about the willingness to push boundaries in how healthcare shows up in culture,' said Shankar Narayanan, CEO of Real Chemistry.
Share
Further cementing its creative leadership, 21GRAMS was named the N o. 2 Healthcare Agency, and Real Chemistry was ranked the No. 2 Healthcare Network globally in the prestigious Cannes Lions Health 2025 rankings, a testament to the company's bold, data-driven storytelling and impact-driven innovation in healthcare.
'Winning at Cannes is not just about the work; it's about the willingness to push boundaries in how healthcare shows up in culture,' said Shankar Narayanan, CEO of Real Chemistry. 'These campaigns reflect our belief that creativity is a force multiplier for health outcomes when paired with science, technology and a deep understanding of humanity. We believe that healthcare deserves to be treated as inspirational and creative as any other category, and our results at Cannes prove what's possible.'
Real Chemistry's 2025 Cannes Lions Highlights
Pharma Lion Win
Gold Lion: 'Friedreich's Back' – Biogen / 21GRAMS
Friedreich's Back is a darkly funny campaign that reimagines 19th-century scientist Nikolaus Friedreich rising from the grave to make sense of a world where a treatment now exists for the disease he discovered. The campaign supported the launch the first FDA-approved treatment for Friedreich ataxia (FA), a rare, genetic and progressive disease that damages the nervous system and impacts muscle control over time.
'This win is extraordinary not just because it's a Gold Lion in Pharma, but because it's for branded work for a rare disease using comedy, which rarely breaks through in shows like these,' said Frank Mazzola, Managing Founder of 21GRAMS and Co-Global Chief Creative Officer at Real Chemistry. 'We didn't do this campaign for awards. We did it for the people who deserve to have their story told, to make a community laugh, connect and help to cope with a devastating condition. 'Friedreich's Back' proves that authentic, client-led creativity still matters – and still wins. Winning means reaching more patients and helping people. That's ultimately our purpose.'
Shortlisted Campaigns
Work from 21GRAMS also received 10 shortlists across the Pharma, Health & Wellness and Sustainable Development Goals categories, representing some of the most acclaimed creative work in the industry this year:
These wins follow a year of strong creative momentum for Real Chemistry, which was named the No. 1 PR Agency by PRWeek, No. 3 in MM+M's Agency 100, and continues to expand its AI-driven storytelling and integrated intelligence platforms for pharma clients worldwide. The firm was recognized as U.S. Agency of the Year at the 2025 SABRE Awards North America and honored with Outstanding Healthcare Agency of the Year at the 2025 PRWeek US Awards. Real Chemistry was ranked as the No. 1 healthcare PR firm globally and No. 2 U.S. PR firm overall by O'Dwyer's, reflecting the agency's consistent leadership across creativity, communications and client impact.
About Real Chemistry
Real Chemistry is a trusted partner to the world's most successful life sciences and healthcare companies. As a leading provider of AI-powered audience analytics and insights, we help the healthcare industry better understand, reach and engage patients and professionals using bold ideas to create human-centric healthcare experiences. Anchored by our culture of innovation and boundless creativity, our 2,000+ experts across the life sciences, marketing communications and technology enable modern medical therapies and those they were designed to help, meet and exceed their potential.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Anavex's blarcasemine nets win in Phase IIb/III Alzheimer's extension study
In another potential win for patients with early-stage Alzheimer's disease, Anavex Life Science's precision medicine blarcasemine has met its primary endpoints in a late-stage trial. Announced at the 2025 Alzheimer's Association International Conference (AAIC), results of the Phase IIb/III ATTENTION-AD (NCT04314934) extension study revealed that blarcasemine, dubbed internally as Anavex 2-73, improved patients' cognitive function by 36.3%, as measured by the Alzheimer's Disease Assessment Scale-Cognitive 13-item (ADAS-COG13) scale. The oral autophagy reactivator also improved daily functioning by 27.6% according to the Clinical Dementia Rating Scale Sum of Boxes (CDR-SB) scale, highlighting the drug's capacity to stave off symptoms of Alzheimer's in the disease's early stages. Like other Alzheimer's-targeting disease modifying therapies (DMTs) on the market, blarcasemine worked best in patients who began taking the drug early, with early initiation offering patients 19.5 months of 'time saved'. The 'time saved' concept describes the period in which a drug can stave off disease progression and allow patients to maintain both functionality and independence. Alzheimer's market competition heats up In recent years, the once stagnant Alzheimer's market has been ignited — primarily driven by the approvals of key anti-amyloid beta monoclonal antibodies (Aβ mAbs) such as Biogen & Eisai's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab), which were given FDA greenlights in 2023 and 2024, respectively. This has driven the market's value significantly, with a forecast from GlobalData, parent company of Clinical Trials Arena, estimating it will be worth $19.3bn in the 8 major markets (8MM includes the US, Germany, France, Italy, Spain, the UK, Japan and China) by 2033. According to a report by Globaldata, these therapies are set to dominate the Alzheimer's market, with Kisunla and Leqembi forecasted to rake in $2bn and $3.5bn, respectively, in the 8MMs. However, neurology analyst at GlobalData, Phillipa Salter noted that anti-Aβ mAbs have been difficult to integrate into clinical practice due to 'their association with significant side effects, including amyloid-related imaging abnormalities (ARIA).' 'They are also only modestly effective, so having alternative treatment options that don't target amyloid will be welcomed in the AD space,' Salter commented. Salter added: 'Significant opportunity therefore exists for Anavex 2-73 with its convenient oral dosing and favourable safety profile.' Instead of targeting and breaking down tau and beta amyloid (Aβ) plaques like Kisunla and Leqembi, Anavex 2-73 works to restore cellular autophagy — a natural process which becomes faulty in early Alzheimer's disease pathology before plaques begin to form. By targeting a mechanism involved in the very early stages of Alzheimer's, blarcasemine differentiates itself from rival therapies at market. "Anavex's blarcasemine nets win in Phase IIb/III Alzheimer's extension study" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Medscape
2 days ago
- Medscape
MHRA Approves First Targeted Drug for SOD1-ALS
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved tofersen (Qalsody, Biogen) for treating amyotrophic lateral sclerosis (ALS) in adults with mutations in the superoxide dismutase 1 (SOD1) gene, also known as SOD1-ALS. The approval makes tofersen the first targeted therapy in the UK against this rare form of motor neurone disease (MND) with a genetic basis. A Rare but Aggressive Condition SOD1-ALS causes the body to produce a misfolded, toxic version of the SOD1 protein. This triggers motor neuron degeneration in the brain and spinal cord. Patients experience progressive muscle weakness, atrophy, respiratory decline, and eventual paralysis and death. SOD1 mutations are responsible for approximately 2% of all ALS cases globally. Over 200 distinct mutations in SOD1 have been identified, each contributing to a wide range of disease progression rates. This variability highlights the importance of developing targeted therapies for SOD1-ALS. How Tofersen Works Tofersen is an antisense oligonucleotide that binds to SOD1 mRNA, promoting its degradation through an RNase H-mediated mechanism. This reduces the production of the toxic SOD1 protein. The drug is administered via intrathecal injection through a lumbar puncture at scheduled intervals, under the supervision of trained healthcare professionals. Success in Clinical Trials The approval was supported by data from the phase 3 VALOR study and its open-label extension (OLE). In the VALOR trial, 108 adults with SOD1-ALS were treated with either intrathecal tofersen (n=72) or placebo (n=36) for 28 weeks. The primary endpoint, the ALSFRS-R score — which assesses bulbar, motor, and respiratory functions — showed a positive trend with tofersen, although the difference was not significant. However, tofersen significantly reduced biomarkers of neurodegeneration, including cerebrospinal fluid (CSF) SOD1 protein levels and plasma neurofilament light chain (NfL) concentrations. By week 28, plasma NfL levels decreased by 55% in the tofersen group, compared to a 12% increase with placebo. Clinical trends suggested improvements in respiratory function, muscle strength, and quality of life. These effects were more pronounced with earlier treatment and during the OLE phase. Safety and Tolerability The most common side effects in tofersen-treated patients included: Back, muscle, and joint pain Fatigue Fever Raised CSF protein levels or white blood cell counts These reactions were generally mild to moderate in severity. Further information, including the Patient Information Leaflet and Summary of Product Characteristics, will be available on the MHRA website within 7 days of approval.
Yahoo
5 days ago
- Yahoo
‘Awards Chatter' Live Pod: Stellan Skarsgard on ‘Sentimental Value,' Lars von Trier and Ingmar Bergman
Last Friday, the veteran Swedish actor Stellan Skarsgard reflected on his life, career and latest project — Joachim Trier's Cannes Grand Prize-winning dramedy Sentimental Value, in which Skarsgard plays a veteran filmmaker who has a complicated family life — during a recording of The Hollywood Reporter's Awards Chatter podcast in front of a packed house at the Karlovy Vary International Film Festival in the Czech Republic. The 74-year-old, who was in town to receive the fest's highest honor for an individual, the Crystal Globe for Outstanding Artistic Contribution to World Cinema, had the crowd enraptured and often in stitches. He discussed how he broke into the biz when he was just 16. He dished on colorful collaborators ranging from Ingmar Bergman to David Fincher. And he dissected his varied adventures in art house films (e.g. his five collaborations with Lars von Trier, most notably 1996's Breaking the Waves), studio movies (e.g. installments of the Dune, Mamma Mia!, Pirates of the Caribbean and MCU franchises) and prestige TV (e.g. the 2019 limited series Chernobyl, for which he won a Golden Globe and was nominated for an Emmy, and the 2022-2025 drama series Andor). More from The Hollywood Reporter HBO's 'Harry Potter' Reveals First Costumed Photo; Casts Neville and Dudley 'A Good Girl's Guide to Murder' Unveils Season 2 Cast and Sneak Peek at Emma Myers' Return Brazil's Jorge Amado Novel 'Tieta' to Be Made Into Film With Suzana Pires, "Feminine Lens" (Exclusive) But Skarsgard seemed most passionate and proud when discussing Sentimental Value, which many — including yours truly — feel showcases his best performance yet. In it, he is both hilarious and heartbreaking as Gustav Borg, a stubborn Norwegian director who for years neglected family in order to focus on his career, but late in life, after his ex-wife's death, tries, in his own way, to make things right with his two daughters (played by the brilliant Renate Reinsve and Inga Ibsdotter Lilleaas), while also pursuing what will probably be his last outing as a director, with a Hollywood starlet (a wonderful Elle Fanning) in the leading role. Be sure to check out the audio of the conversation at the top of this post, as well as all of Team THR's coverage of the 2025 Karlovy Vary International Film Festival — the first since the death of longtime festival president Jirí Bartoska — at which other special guests included Michael Douglas, Dakota Johnson, Peter Sarsgaard and Vicky Krieps, and at which the films Better Go Mad in the Wild, Bidad, Sand City and Forensics were awarded top prizes. Best of The Hollywood Reporter The 40 Best Films About the Immigrant Experience Wes Anderson's Movies Ranked From Worst to Best 13 of Tom Cruise's Most Jaw-Dropping Stunts Solve the daily Crossword
